In Phase 1 portion of trial, WVE-007 improved body composition by inducing fat loss, including harmful visceral fat, while maintaining muscle; data continue to support once or twice-yearly dosing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results